Leerink Reaffirms Neovasc (NVCN) at 'Outperform' Amid Boston Scientific Deal

Go back to Leerink Reaffirms Neovasc (NVCN) at 'Outperform' Amid Boston Scientific Deal

Neovasc (NVCN) Agrees to Sell Tissue Processing Tech to Boston Scientific (BSX) in $75M Deal

December 2, 2016 7:03 AM EST

Neovasc Inc. (Nasdaq: NVCN) announced that Boston Scientific Corporation (NYSE: BSX), a global medical technology leader, has agreed to acquire Neovasc's tissue processing technology and facility for approximately US$67,909,800. Concurrently, Boston Scientific has committed to invest an additional US$7,090,200 in Neovasc for a 15% equity interest in the Company.

"Boston... More

Boston Scientific (BSX) Accquires Certain Assets, 15% Equity Stake in of Neovasc (NVCN) for $75M

December 2, 2016 7:03 AM EST

Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire certain manufacturing assets and capabilities of the Neovasc, Inc., (NASDAQ: NVCN) (TSX: NVC) advanced biological tissue business, as well as a 15% equity stake in Neovasc, for a... More